Sign up to our newsletter Subscribe
2023 OHE Annual Report to the Charity Commission
Cell and Gene Therapies
Cell and gene therapies offer substantial therapeutic benefits but are expensive and often have a limited evidence base at launch. There are concerns over affordability and long-term cost-effectiveness, as well as uncertainty as to whether their value is accurately captured by current HTA methods.
Early Experience with Health Technology Assessment of Gene Therapies in the United States: Pricing and Paying for Cures
